RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Abu Dhabi Public Health Centre (ADPHC) has vaccinated nearly 300,000 people across Abu Dhabi, Al Ain Region, and Al Dhafra with the seasonal flu vaccine as part of its 2024–2025 campaign, a 45 percent ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The efficacy results are "a significant milestone in our effort to reduce the burden of influenza in older adults," Moderna CEO Stephane Bancel said in a release. "The severity of this past flu season ...